|
1
|
Dunn MW and Kazer MW: Prostate cancer
overview. Semin Oncol Nurs. 27:241–250. 2011. View Article : Google Scholar
|
|
2
|
Ha HK, Lee W, Park HJ, et al: Clinical
significance of CXCL16/CXCR6 expression in patients with prostate
cancer. Mol Med Rep. 4:419–424. 2011.PubMed/NCBI
|
|
3
|
Gosselaar C, Roobol MJ, Roemeling S, van
der Kwast TH and Schröder FH: Screening for prostate cancer at low
PSA range: the impact of digital rectal examination on tumor
incidence and tumor characteristics. Prostate. 67:154–161. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Katahira K, Takahara T, Kwee TC, et al:
Ultra-high-b-value diffusion-weighted MR imaging for the detection
of prostate cancer: evaluation in 201 cases with histopathological
correlation. Eur Radiol. 21:188–196. 2011. View Article : Google Scholar
|
|
5
|
Stewart GD, Gray K, Pennington CJ, et al:
Analysis of hypoxia-associated gene expression in prostate cancer:
lysyl oxidase and glucose transporter-1 expression correlate with
Gleason score. Oncol Rep. 20:1561–1567. 2008.PubMed/NCBI
|
|
6
|
Arora R, Koch MO, Eble JN, et al:
Heterogeneity of Gleason grade in multifocal adenocarcinoma of the
prostate. Cancer. 100:2362–2366. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Jiang YW and Chen LA: microRNAs as tumor
inhibitors, oncogenes, biomarkers for drug efficacy and outcome
predictors in lung cancer (review). Mol Med Rep. 5:890–894.
2012.PubMed/NCBI
|
|
8
|
Fang YX and Gao WQ: Roles of microRNAs
during prostatic tumorigenesis and tumor progression. Oncogene.
2013.PubMed/NCBI
|
|
9
|
Hamamoto J, Soejima K, Yoda S, et al:
Identification of microRNAs differentially expressed between lung
squamous cell carcinoma and lung adenocarcinoma. Mol Med Rep.
8:456–462. 2013.PubMed/NCBI
|
|
10
|
Nazarov PV, Reinsbach SE, Muller A, et al:
Interplay of microRNAs, transcription factors and target genes:
linking dynamic expression changes to function. Nucleic Acids Res.
41:2817–2831. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Marcucci G, Maharry KS, Metzeler KH, et
al: Clinical role of microRNAs in cytogenetically normal acute
myeloid leukemia: miR-155 upregulation independently identifies
high-risk patients. J Clin Oncol. 31:2086–2093. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yang M, Shen H, Qiu C, et al: High
expression of miR-21 and miR-155 predicts recurrence and
unfavourable survival in non-small cell lung cancer. Eur J Cancer.
49:604–615. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Huang X, Taeb S, Jahangiri S, et al:
MiRNA-95 mediates radioresistance in tumors by targeting the
sphingolipid phosphatase SGPP1. Cancer Res. 2013.PubMed/NCBI
|
|
14
|
Huang X and Jia Z: Construction of
HCC-targeting artificial miRNAs using natural miRNA precursors. Exp
Ther Med. 6:209–215. 2013.PubMed/NCBI
|
|
15
|
Shi XB, Xue L, Ma AH, et al: MiR-125b
promotes growth of prostate cancer xenograft tumor through
targeting pro-apoptotic genes. Prostate. 71:538–549. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhang CM, Zhao J and Deng HY: MiR-155
promotes proliferation of human breast cancer MCF-7 cells through
targeting tumor protein 53-induced nuclear protein 1. J Biomed Sci.
20:792013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Powell-Coffman JA and Coffman CR:
Apoptosis: Lack of oxygen aids cell survival. Nature. 465:554–555.
2010. View
Article : Google Scholar : PubMed/NCBI
|
|
18
|
Li T, Kon N, Jiang L, et al: Tumor
suppression in the absence of p53-mediated cell-cycle arrest,
apoptosis, and senescence. Cell. 149:1269–1283. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Petrocca F, Visone R, Onelli MR, et al:
E2F1-regulated microRNAs impair TGFbeta-dependent cell-cycle arrest
and apoptosis in gastric cancer. Cancer Cell. 13:272–286. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Higgs G and Slack F: The multiple roles of
microRNA-155 in Oncogenesis. J Clin Bioinforma. 3:172013.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Streicher WW, Lopez MM and Makhatadze GI:
Annexin I and annexin II N-terminal peptides binding to S100
protein family members: specificity and thermodynamic
characterization. Biochemistry. 48:2788–2798. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lokman NA, Ween MP, Oehler MK and
Ricciardelli C: The role of annexin A2 in tumorigenesis and cancer
progression. Cancer Microenviron. 4:199–208. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Paweletz CP, Ornstein DK, Roth MJ, et al:
Loss of annexin 1 correlates with early onset of tumorigenesis in
esophageal and prostate carcinoma. Cancer Res. 60:6293–6297.
2000.PubMed/NCBI
|
|
24
|
Jin Y, Wang S, Chen W, et al: Annexin A7
suppresses lymph node metastasis of hepatocarcinoma cells in a
mouse model. BMC Cancer. 13:5222013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Srivastava M, Bubendorf L, Srikantan V, et
al: ANX7, a candidate tumor suppressor gene for prostate cancer.
Proc Natl Acad Sci USA. 98:4575–4580. 2001. View Article : Google Scholar : PubMed/NCBI
|
